← Back to Search

Unknown

VB119 for Kidney Disease

Phase 1 & 2
Waitlist Available
Research Sponsored by ACELYRIN Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 18 months
Awards & highlights

Summary

This trial is testing a new drug, VB119, to see if it is safe and effective for people with a certain type of cancer.

Who is the study for?
This trial is for adults with a confirmed diagnosis of primary Membranous Nephropathy (kidney disease) within the last 10 years, showing high levels of protein in urine. Participants must have stable blood pressure and agree to use effective contraception. Those with certain infections, diabetes, low white blood cell counts, or other autoimmune diseases like lupus are excluded.Check my eligibility
What is being tested?
The study tests VB119's safety and effectiveness on kidney function in patients with Membranous Nephropathy. It's an early-stage trial where doses increase over time among different groups to find the right balance between benefits and side effects.See study design
What are the potential side effects?
Specific side effects for VB119 aren't listed here but may include typical drug reactions such as nausea, allergic responses, potential impact on blood cells or organ functions which will be closely monitored throughout the trial.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 18 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 18 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of Clinical Laboratory Assessments
Incidence of Treatment-Emergent Adverse Events
Secondary outcome measures
% of Patients with Anti-Drug Antibodies
% of patients achieving complete remission of proteinuria
Anti-PLA2R Antibody Assessment
+3 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: VB119 dose escalationExperimental Treatment1 Intervention
Dose escalation phase followed by a dose expansion phase. VB119 to be administered as intravenous infusions.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Membranous Glomerulonephritis (MN) include immunosuppressive agents such as cyclophosphamide, calcineurin inhibitors (e.g., cyclosporine, tacrolimus), and corticosteroids. These treatments work by suppressing the immune system to reduce the production of antibodies that attack the glomerular basement membrane, thereby decreasing inflammation and preventing further kidney damage. This is crucial for MN patients as it helps to preserve kidney function, reduce proteinuria, and improve long-term outcomes. Understanding these mechanisms is important for tailoring treatment plans and managing potential side effects effectively.
The management of membranous nephropathy-an update.[Therapeutic strategies for membranous nephropathy: guideline from the Italian Society of Nephrology].Recent developments in the management of membranous nephropathy.

Find a Location

Who is running the clinical trial?

ACELYRIN Inc.Lead Sponsor
8 Previous Clinical Trials
1,048 Total Patients Enrolled
Tenet MedicinesLead Sponsor
1 Previous Clinical Trials
1 Total Patients Enrolled
ValenzaBio, Inc.Lead Sponsor
2 Previous Clinical Trials
39 Total Patients Enrolled

Media Library

VB119 (Unknown) Clinical Trial Eligibility Overview. Trial Name: NCT04652570 — Phase 1 & 2
Membranous Glomerulonephritis Research Study Groups: VB119 dose escalation
Membranous Glomerulonephritis Clinical Trial 2023: VB119 Highlights & Side Effects. Trial Name: NCT04652570 — Phase 1 & 2
VB119 (Unknown) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04652570 — Phase 1 & 2
~1 spots leftby Jul 2025